Enanta Pharmaceuticals Inc expected to post a loss of $1.45 a share - Earnings Preview

Enanta Pharmaceuticals

02/08/2024 14:01

* Enanta Pharmaceuticals Inc  ENTA.OQ   ENTA.O  is expected
to show a fall in quarterly revenue when it reports  results on
August 5 (estimated) for the period ending June 30 2024
    * The Watertown Massachusetts-based  company is expected to
report
a 9.1% decrease in revenue to $17.178 million from $18.89
million a year ago, according to the mean estimate from 7
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Enanta Pharmaceuticals
Inc is
for a loss of $1.45 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Enanta
Pharmaceuticals Inc is $22.00​, above​ its last closing price
of $14.81. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -1.39       -1.30      -1.47     Missed  -13.2
 Dec. 31 2024  -1.19       -1.19      -1.58     Missed  -32.3
 Jan. 1 0001   -2.17       -2.15      -1.33     Beat    38​
 Jun. 30 2023  -2.37       -2.34      -1.86     Beat    20.4
 ​​Mar.        -1.94       -1.98      -1.79     Beat    9.6
 31 2023                                                
 Dec. 31 2022  -1.59       -1.59      -1.39     Beat    12.9​
 Sep. 30 2022  -1.40       -1.35      -1.27     Beat    6.1
 Jun. 30 2022  -1.46       -1.39      -1.53     Missed  -10.4
 This summary was machine generated August 2 at 13:01 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)